a Programa de Pós-graduação em Biociências e Biotecnologia em Saúde , Instituto Aggeu Magalhães (IAM), Fundação Oswaldo Cruz (FIOCRUZ) , Recife , Pernambuco , Brasil.
b Programa de Pós-graduação em Ciências da Saúde , Universidade de Pernambuco (UPE) , Recife , Pernambuco , Brasil.
Pathog Glob Health. 2019 May;113(3):143-148. doi: 10.1080/20477724.2019.1623546. Epub 2019 May 29.
Mass drug administration (MDA) is the main counter-transmission strategy of the Global Programme to Eliminate Lymphatic Filariasis. In endemic countries, there are areas where MDA is not required. However, there is no standard approach in these areas, and studies are important to evaluate the epidemiological status. This study aimed to investigate lymphatic filariasis and strategies developed for its control in an area where MDA is not required. Together with the 2018 morbidity evaluation, a survey was conducted using point-of-care immunochromatographic test-AD12 tests for diagnostic screening in an area where MDA is not required. The methodology also included desk research based on Health Department reports of the control activities for lymphatic filariasis during 2003-2016. Among the 934 cases investigated in 2018, there was a 0.64% prevalence of circulating filarial antigen positive, comprising five adults and one 2-year-old child. Six patients aged 39-63 years had filarial disease. Fourteen surveys have already been conducted as control activities, and since 2009, there have been no positive cases. This study showed that the prevalence of antigenemia decreased from 2.97% in 2003 to 0.64% in 2018. Moreover, the transmission of filariasis infection was under control in this area. Our study provides insights into the surveillance phase by identifying areas of low transmission and where MDA is not required. Although we have not identified cases of filarial infection, there is a need to provide services that will provide assist those already affected with morbidity and help reduce and prevent disability.
大规模药物治疗(MDA)是全球消灭淋巴丝虫病规划的主要反传播策略。在流行国家,有一些地区不需要 MDA。然而,这些地区没有标准的方法,因此研究对于评估流行病学状况非常重要。本研究旨在调查无需 MDA 的地区的淋巴丝虫病及其控制策略。与 2018 年发病率评估一起,在无需 MDA 的地区进行了一项调查,使用即时免疫层析试验 AD12 检测进行诊断筛查。该方法还包括基于卫生部门报告的 2003-2016 年期间淋巴丝虫病控制活动的桌面研究。在 2018 年调查的 934 例病例中,有 0.64%的人循环性丝虫抗原阳性,包括 5 名成年人和 1 名 2 岁儿童。6 名 39-63 岁的患者患有丝虫病。已经进行了 14 次调查作为控制活动,自 2009 年以来没有发现阳性病例。本研究表明,抗原血症的患病率从 2003 年的 2.97%降至 2018 年的 0.64%。此外,该地区的丝虫病传播得到了控制。我们的研究通过确定低传播地区和无需 MDA 的地区,为监测阶段提供了一些见解。尽管我们没有发现丝虫感染的病例,但仍需要提供服务,以帮助那些已经受到影响的人减轻和预防残疾。